Overview

Efficacy, Pharmacokinetics and Safety of Testosterone

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label study of a single and repeated application of three dose levels of topical testosterone in hypogonadal males with morning serum testosterone concentrations < 297 ng/dL.
Phase:
Phase 2
Details
Lead Sponsor:
Ferring Pharmaceuticals
Treatments:
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate